U.S. markets closed

Zynex, Inc. (ZYXI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
16.70+0.77 (+4.83%)
At close: 4:00PM EDT
Full screen
Loading interactive chart...
  • Why Zynex's Stock Is Trading Higher Today

    Why Zynex's Stock Is Trading Higher Today

    Zynex (NASDAQ: ZYXI) shares are trading higher on Monday after H.C. Wainwright & Co upgraded the stock from Neutral to Buy and announced a price target of $25 per share.Zynex is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products.The company designs, manufacture, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. It also develops and markets medical devices for non-invasive cardiac monitoring, the products of which are under development.The company markets Zynex-manufactured products which include NexWave, NeuroMove, InWave, Non-Invasive Blood Volume Monitor and others.Zynex shares were trading up 7.04% at $16.58 on Monday during the time of publication. The stock has a 52-week high of $29.73 and a 52-week low of $7.51.Latest Ratings for ZYXI DateFirmActionFromTo Sep 2020HC Wainwright & Co.UpgradesNeutralBuy Sep 2020Northland Capital MarketsUpgradesMarket PerformOutperform Jul 2020B. Riley FBRUpgradesNeutralBuy View More Analyst Ratings for ZYXI View the Latest Analyst RatingsSee more from Benzinga * Why Huami's Stock Is Trading Higher Today * Take A Look At The Former Michigan Mansion Of Detroit Pistons Legend Joe Dumars * Why Cemex's Stock Is Trading Higher Today(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Zynex Reaches 400 Salesperson Milestone Ahead of Schedule
    PR Newswire

    Zynex Reaches 400 Salesperson Milestone Ahead of Schedule

    Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced reaching four hundred sales reps in the U.S.